153 results
8-K
EX-99.1
OPGN
Opgen Inc
29 Apr 24
OpGen Provides Update on Business Operations and Strategic Opportunities
4:28pm
statements regarding OpGen’s future plans and goals constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act
8-K
EX-99.1
OPGN
Opgen Inc
23 Apr 24
OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K
4:30pm
statements regarding OpGen’s future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act
SC 14F1
OPGN
Opgen Inc
3 Apr 24
Statement regarding change in majority of directors
5:29pm
the purposes and responsibilities of the committee, including:
annually reviewing and recommending to our Board corporate goals and objectives … of our Chief Executive Officer in light of such corporate goals and objectives and recommending to our Board the compensation of our Chief Executive
8-K
EX-99.1
qxuzi
29 Mar 24
OpGen Announces Acquisition of Preferred Stock by David Lazar
2:35pm
8-K
EX-99.1
i7syjfuy6ch81hpohq
14 Nov 23
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
4:40pm
8-K
EX-99.1
ggh9ign4gck
16 Oct 23
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-99.1
d90 9zsdj7vcosy6y7o
10 Aug 23
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
4:31pm
8-K
EX-99.1
jt6jqcapzid iflm
15 May 23
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
5:11pm
8-K
EX-99.1
bjd0jk
4 May 23
OpGen Announces Pricing of $3.5 Million Public Offering
4:47pm
8-K
EX-99.2
qs3s81c7
4 May 23
OpGen Announces Pricing of $3.5 Million Public Offering
4:47pm
424B3
1f7i6ko7yuae4pzio9py
3 May 23
Prospectus supplement
4:43pm
CORRESP
30xy2
27 Apr 23
Correspondence with SEC
12:00am
8-K
EX-99.1
onxzs40i c1t
19 Apr 23
OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare
8:07am
8-K
EX-99.1
68o08
18 Apr 23
OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel
4:45pm